

AG Mednet, Median Technologies to conduct clinical programs in China

09 July 2019 | News

AG Mednet is delivering support to Median for its growing global portfolio of trials including its large programs in China.



French company Median Technologies, The Imaging Phenomics Company® and US based AG Mednet have renewed their partnership to use AG Mednet's global infrastructure for the collection, QC and delivery of medical images and ancillary data in support current and future clinical trials and programs.

Median provides solutions and services for medical image analysis and management in oncology trials globally. AG Mednet works with global CROs, providing technology solutions for clinical trial adjudication and imaging.

Through the partnership, AG Mednet is delivering support to Median for its growing global portfolio of trials including its large programs in China. AG Mednet is pioneer in providing imaging technology and support to the clinical trial industry. The company's Judi // Imaging platform provides the market-leading functionality, customer support and global footprint necessary to collect clinical trial image data, properly de-identify it to ensure regulatory compliance, apply advanced, automated quality-assurance processes to insure the data is protocol-compliant and readily usable, and deliver it reliably and securely to trial repositories.

"Median Technologies has long been an important European partner and renewing and growing our partnership will continue to increase both companies' footprint," said Abraham Gutman, president & CEO of AG Mednet. "While investigator sites in China have represented a significant percentage of our global users for many years, with Median we will also support its local CRO business, delivering timely and quality data to Median's China-based infrastructure."